Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives.
Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F. Personeni N, et al. Among authors: bregni g. Cancers (Basel). 2021 Sep 7;13(18):4506. doi: 10.3390/cancers13184506. Cancers (Basel). 2021. PMID: 34572729 Free PMC article. Review.
Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial.
Camera S, Akin Telli T, Woff E, Vandeputte C, Kehagias P, Guiot T, Critchi G, Wissam Y, Bregni G, Trevisi E, Pretta A, Senti C, Leduc S, Gkolfakis P, Hoerner F, Rothé F, Sclafani F, Flamen P, Deleporte A, Hendlisz A. Camera S, et al. Among authors: bregni g. Cancers (Basel). 2020 Sep 24;12(10):E2752. doi: 10.3390/cancers12102752. Cancers (Basel). 2020. PMID: 32987838 Free PMC article.
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Akin Telli T, Bregni G, Camera S, Deleporte A, Hendlisz A, Sclafani F. Akin Telli T, et al. Among authors: bregni g. Cancer Lett. 2020 Jan 28;469:142-150. doi: 10.1016/j.canlet.2019.10.036. Epub 2019 Oct 25. Cancer Lett. 2020. PMID: 31669518 Review.
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.
Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Vandeputte C, et al. Among authors: bregni g. Clin Colorectal Cancer. 2021 Dec;20(4):326-333. doi: 10.1016/j.clcc.2021.07.006. Epub 2021 Jul 24. Clin Colorectal Cancer. 2021. PMID: 34404621 Clinical Trial.
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.
Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A. Camera S, et al. Among authors: bregni g. Clin Colorectal Cancer. 2020 Dec;19(4):311-318.e1. doi: 10.1016/j.clcc.2020.05.007. Epub 2020 May 29. Clin Colorectal Cancer. 2020. PMID: 32631787 Clinical Trial.
JCOG0603: Are We Really Sure This Was a Negative Trial?
Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F. Saude Conde R, et al. Among authors: bregni g. J Clin Oncol. 2022 Mar 1;40(7):803-805. doi: 10.1200/JCO.21.02299. Epub 2022 Jan 13. J Clin Oncol. 2022. PMID: 35025615 No abstract available.
46 results